The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review
Cataldo Procacci, Maria Rosaria Gualano, Leonarda Maurmo, Ilaria Valentini, Sofia Mao, Walter Ricciardi · 2026
Read The Clinical and Economic Impact of Biologic Agents in Asthma Management: a Systematic Review by Cataldo Procacci, Maria Rosaria Gualano, Leonarda Maurmo, Ilaria Valentini, Sofia Mao, Walter Ricciardi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13272213.txt.
Description
Cataldo Procacci is lead author of a 2026 systematic review of biologic therapies for severe asthma, weighing clinical benefit and economic impact together in real-world populations. These targeted antibody drugs have transformed severe asthma care, but combined clinical and cost evidence was incomplete.
Searching two databases for 2014 to 2024 studies, the team kept 27 studies covering 59,958 patients, mostly observational. All drugs cut flare-ups by 46 to 86 percent, hospitalisations fell 57 to 85 percent, and emergency visits fell 52 to 72 percent. Patients dependent on oral steroids dropped by 53 to 67 percent. Savings from reduced care partly offset drug costs, giving favourable cost per flare-up avoided, though the authors flag methodological limits.
Catalog record
| CREATOR | Cataldo Procacci, Maria Rosaria Gualano, Leonarda Maurmo, Ilaria Valentini, Sofia Mao, Walter Ricciardi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 92634 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |